Valensa Yosephia, Peter Yustian Atmaja, Arif Nur Muhammad Ansori, Ahmad Affan Ali Murtadloef, Viol Dhea Kharism, Putu Angga Wiradana, I Gede Widhiantara, Sukma Sahadewa, Maksim Rebezov, Nikolai Maksimiuk, Evgeniy Kolesnik, Marina Derkho, I Natalia Koriagina, Aswin Rafif Khairullah, Fara Disa Durry, Rahadian Zainul
Monoclonal antibodies composed entirely of human immunoglobulin G4 that specifically target programmed death-1 (PD-1) are referred to as Nivolumab and Pembrolizumab. Monoclonal antibody of anti-PD-1 type for glioblastoma was found to be beneficial and harmless in preclinical research. Monoclonal antibody of anti-PD-1 (Pembrolizumab, Nivolumab) versus standard therapy for glioblastoma was systematically compared in terms of overall survival (OS), progression-free survival (PFS), and adverse events (AE). Pubmed, Scopus, Cochrane, and Clinicaltrials.gov databases were systematically searched through May 2023 for phase I or later RCTs reporting outcomes of interest. Inclusion RCTs criteria are adult population (>18 years old) with newly diagnosed or recurring cases of glioblastoma and have received immunotherapy with PD-1 inhibitors or standard treatment. For both OS and PFS, pooled effects estimates were computed using the approach of Cox proportional hazards regression. A computation was conducted on RCTs comprising 1680 patients from 4 included studies. Comparing anti-PD-1 monoclonal antibody to standard therapy, neither PFS nor OS improved at the median (HR = 1.08, 95% CI = 0.87-1.34, P = 0.51; P = 0.29; P = 0.29; and P = 0.29, 95% CI = 0.85-1.74, respectively). Furthermore, neither methylated nor un-methylated MGMT status benefits from anti-PD-1 monoclonal antibody (HR = 1.06, 95% CI = 0.89-1.27, P = 0.49; and HR = 1.29, 95% CI = 1.10-1.53, P = 0.002, respectively) in terms of overall survival. The anti-PD-1 antibody group experienced a greater incidence of AE (RR = 1.03, 95% CI = 0.94-1.14, P = 2.51). Anti-PD-1 monoclonal antibody did not demonstrate any clinical advantage over standard treatment for glioblastoma, according to this metaanalysis of four RCTs. © 2024, Sami Publishing Company. All rights reserved.
Master Program of Immunology, Postgraduate School, Universitas Airlangga, Surabaya, Indonesia; Department of Neurosurgery, dr. Moewardi General Hospital, Surakarta, Indonesia; Postgraduate School, Universitas Airlangga, Surabaya, Indonesia; Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Surabaya, Indonesia; Department of Research and Development, Jalan Tengah, Surabaya, Indonesia; Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia; Research Group of Biological Health, Study Program of Biology, Faculty of Health and Science, Universitas Dhyana Pura, Bali, Indonesia; Faculty of Medicine, Universitas Wijaya Kusuma Surabaya, Surabaya, Indonesia; V.M. Gorbatov Federal Scientific Center for Food Systems of the Russian Academy of Sciences, Moscow, Russian Federation; The Institute of Medical Education, Yaroslav-the-Wise Novgorod State University, Velikiy Novgorod, Russian Federation; Department of Physiology, Ethology and Biochemistry of Animals, Russian State Agrarian University - Moscow Agricultural Academy named after K.A. Timiryazev, Moscow, Russian Federation; Department of Natural Sciences, South Ural State Agrarian University, Troitsk, Russian Federation; E.A. Vagner Perm State Medical University, Perm Krai, Russian Federation; Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia; Faculty of Medicine, Universitas Pembangunan Nasional “Veteran” Jawa Timur, Surabaya, Indonesia; Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, Padang, Indonesia; Center for Advanced Material Processing, Artificial Intelligence and Biophysics Informatics (CAMPBIOTICS), Universitas Negeri Padang, Padang, Indonesia
